Mantle Cell Lymphoma | Clinical

Exploring a Time-to-Relapse Analysis for Rituximab and Transplant in MCL

July 24, 2021

Peter A. Riedell, MD, discusses the clinical implication of using frontline high-dose rituximab-based therapy and autologous hematopoietic cell transplantation in patients with mantle cell lymphoma in an analysis of time to relapse.

Real-World Treatment for Patients With MCL Reveals Discrepancy Between Actual Care and Clinical Trial Recommendations

June 15, 2021

A study of treatment patterns in adult patients with mantle cell lymphoma revealed a discrepancy between actual patterns of care and recommendations based on clinical trials, according to a poster presented at the European Hematology Association 2021 Virtual Congress.

Rituximab Maintenance Improves Time-to-Next Treatment and OS in Patients With Mantle Cell Lymphoma

June 14, 2021

Time-to-next treatment and overall survival were improved in a real-world study evaluating patients who received rituximab maintenance after first-line treatment with bendamustine and rituximab or R-CHOP in patients with mantle cell lymphoma, according to a retrospective analysis presented at the European Hematology Association 2021 Virtual conference.

Tazemetostat Elicits Preclinical Anti-Tumor Responses in MCL Cell Lines With BTK Resistance

May 26, 2021

Mantle cell lymphoma cell lines with intrinsic resistance to BTK inhibitors displayed anti-tumor activity on treatment with tazemetostat as monotherapy or in combination with zanubrutinib, according to data from a preclinical analysis.